Fig. 5: CJF-III-288 in combination with the anti-CoRBS Ab 17b delays viral rebound in HIV-1JRCSF-infected humanized mice. | Nature Communications

Fig. 5: CJF-III-288 in combination with the anti-CoRBS Ab 17b delays viral rebound in HIV-1JRCSF-infected humanized mice.

From: The asymmetric opening of HIV-1 Env by a potent CD4 mimetic enables anti-coreceptor binding site antibodies to mediate ADCC

Fig. 5: CJF-III-288 in combination with the anti-CoRBS Ab 17b delays viral rebound in HIV-1JRCSF-infected humanized mice.The alternative text for this image may have been generated using AI.

a Experimental outline. Cartoons were created in BioRender. Kumar, P. (2025) https://BioRender.com/y37a8as. Humanized NSG-Tg(IL15) mice were intraperitoneally infected with HIV-1JRCSF and assessed for plasma viral loads (PVLs) by quantitative real-time PCR. At PVLs of 104-105 copies/ml, mice were subcutaneously administered combination antiretroviral therapy (ART, consisting of tenofovir disoproxil fumarate, emtricitabine, and dolutegravir). PVLs were stably suppressed for >3 weeks on ART. A day before ART interruption, mice were divided into three groups: Mock-treated (black) (n = 2), BNM-III-170 + 17b (purple) (n = 4), and CJF-III-288 + 17b (cyan) (n = 3). The CD4mc were administered at 3, 3, 1, 1, and 1 mg on consecutive days from day 0 (D0) to day 4 (D4), and 17b antibody was administered at 1.5 mg on D0 and 0.75 mg on D2 and D4. b PVLs obtained post-ATI in individual mice from the mock-treated (black), BNM-III-170 + 17b (purple), and CJF-III-288 + 17b groups (cyan). PVL measurements for individual mice are shown as dashed lines, and mean values for each regimen are shown as solid lines. Source data for b are provided as a Source Data file.

Back to article page